MANILA – In a scathing critique that spotlights a glaring bottleneck in healthcare access, the Pharmaceutical and Healthcare Association of the Philippines (PHAP) has slammed the sluggish approval process for new cancer drugs, warning that bureaucratic delays are denying Filipino patients cutting-edge treatments already saving lives abroad. The call, issued during a December 9, 2025, forum on oncology innovation, underscores a systemic snag where novel therapies languish in regulatory limbo for up to two years – far longer than regional peers like Thailand (6-12 months) and Singapore (3-9 months) – leaving oncologists and patients in a frustrating holding pattern.
PHAP President Teodoro Padilla didn’t mince words on the human toll: “Every month of delay means thousands of Filipinos miss out on therapies that could extend life or improve quality of life.” He cited blockbuster drugs like osimertinib for lung cancer and trastuzumab deruxtecan for breast cancer, approved globally years ago but still awaiting Food and Drug Administration (FDA) nods here. “These aren’t experimental – they’re standard of care in Europe and the US,” Padilla stressed, blaming a backlog of over 1,500 pending applications and outdated evaluation frameworks that prioritize generics over breakthrough biologics.
The FDA, under Director General Samuel Zacate, has pledged reforms – digitizing submissions, hiring 50 more evaluators, and fast-tracking oncology filings under the “compassionate use” pathway – but PHAP insists it’s too little, too late. “We’ve seen incremental gains, but the pipeline is clogged,” Padilla noted, urging a dedicated oncology review lane and alignment with ASEAN mutual recognition agreements to slash timelines by 50%. Health Secretary Teodoro Herbosa echoed the urgency in a separate statement: “Cancer is the third leading cause of death here – we can’t afford delays when lives are on the line.”
For patients like Maria Santos, a 52-year-old Quezon City teacher battling stage IV breast cancer, the lag is personal. “I’ve heard of drugs that could shrink my tumors, but they’re not here yet,” she shared, her voice cracking. “Waiting feels like fighting with one hand tied.” With 159,000 new cancer cases yearly and survival rates lagging regional averages, advocates like the Cancer Coalition Philippines demand immediate action: “This isn’t red tape; it’s a death sentence by delay.”
As the holidays dawn with their themes of hope and healing, PHAP’s plea rings resonant: Streamline approvals, or let innovation idle while patients pay the price. In a nation racing toward universal health care, the real cure might just be cutting the queue – one lifesaving stamp at a time.